## Barriers & enablers to caring for people who regularly use methamphetamine – Sydney GP perspectives

## Antony Bolton<sup>1,2</sup>, Catherine Spooner<sup>1</sup>, Nadine Ezard<sup>3,4</sup>, Mark Harris<sup>1</sup>

<sup>1</sup>Centre for Primary Health Care & Equity, UNSW Sydney NSW 2052, <sup>2</sup>The Hamilton Centre, Austin Health, Heidelberg VIC 3084, <sup>3</sup>National Centre for Clinical Research on Emerging Drugs, UNSW Sydney NSW 2052, <sup>4</sup>Alcohol & Drug Service, St Vincent's Hospital, Darlinghurst NSW 2010

Presenter's email: actual@drantonybolton.care

**Introduction:** People who regularly use methamphetamine (PWRUM) are experiencing harms to physical and psychological health[1,2,3]. It is surprising, therefore, to learn that they visit General Practitioners (GPs) more frequently than the general population[4]. There is little in the literature to help us understand GPs' opinions on caring for PWRUM and explain why these frequent attendances aren't translating into better outcomes.

**Method:** AB conducted semi-structured interviews with 14 GPs practicing in the Greater Sydney area about their experiences of providing general practice-based care for PWRUM. Demographic & scope of practice data were collected to ensure a broad sample. Transcripts were analysed thematically using an established framework. Levesque (2013) conceptualises access to care as depending on the "ability" of consumers to navigate a series of provider domains[5] and is therefore patient-focused. We recruited to thematic saturation.

**Key Findings:** GPs described a range of barriers & enablers across the domains described by Levesque (2013). This presentation will focus on the attitudinal, social and personal factors identified. Barriers included poor staff attitudes; the impact of stigma and stereotyping; and the emotional impact on the practitioner of consultations with PWRUM. Enablers included adopting a non-judgemental, harm reduction-orientated approach to patients; being flexible around how care is provided; and ensuring good continuity of care. Other factors will be briefly described.

**Implications for Practice:** The barriers and enablers identified by our GP participants described via a patient-focused access framework, could be used to inform improved educational content for GPs in training, established GPs and practice staff; better funding models; and new models of care that will better meet the needs of this group – relating to both methamphetamine use and the effects this can have an health in general.

## References

- 1. Degenhardt L, Sara G, McKetin R, Roxburgh A, Dobbins T, Farrell M, et al. Crystalline methamphetamine use and methamphetamine-related harms in Australia. Drug Alcohol Rev. 2017;36(2):160-70.
- 2. Darke S, Kaye S, Duflou J. Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study. Addiction. 2017;112(12):2191-201.
- 3. Man N, Sisson SA, McKetin R, Chrzanowska A, Bruno R, Dietze PM, et al. Trends in methamphetamine use, markets and harms in Australia, 2003-2019. Drug Alcohol Rev. 2022;41(5):1041-52.
- 4. McKetin R, Degenhardt L, Shanahan M, Baker AL, Lee NK, Lubman DI. Health service utilisation attributable to methamphetamine use in Australia: Patterns, predictors and national impact. Drug Alcohol Rev. 2018;37(2):196-204.

5. Levesque J-F, Harris MF, Russell G. Patient-centred access to health care: conceptualising access at the interface of health systems and populations. International Journal for Equity in Health. 2013;12(1):18.

**Disclosure of Interest Statement:** No pharmaceutical grants were received in the development of this study. This work was supported by the RACGP & Commonwealth Government.